Cargando…
In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity.
The novel indoloquinone compound EO-9 is shortly to undergo phase I clinical evaluation as a potential bioreductive drug. Preclinical studies have shown that EO-9 has greater activity against cells derived from human solid tumours than leukaemias in vitro. The results of this study extend the precli...
Autores principales: | Phillips, R. M., Hulbert, P. B., Bibby, M. C., Sleigh, N. R., Double, J. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977599/ https://www.ncbi.nlm.nih.gov/pubmed/1558788 |
Ejemplares similares
-
DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9.
por: Plumb, J. A., et al.
Publicado: (1994) -
Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.
por: Maliepaard, M., et al.
Publicado: (1995) -
EO9: relationship between DT-diaphorase levels and response in vitro and in vivo.
por: Collard, J., et al.
Publicado: (1995) -
A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9
por: Choudry, G A, et al.
Publicado: (2001) -
Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status.
por: Bibby, M. C., et al.
Publicado: (1991)